AC Immune SA
ACIU
$1.77
-$0.11-5.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.29M | 29.46M | 759.70K | -- | 16.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.29M | 29.46M | 759.70K | -- | 16.72M |
| Cost of Revenue | 17.97M | 16.74M | 18.95M | 17.34M | 16.54M |
| Gross Profit | -16.68M | 12.72M | -18.19M | -17.34M | 177.30K |
| SG&A Expenses | 4.54M | 4.34M | 5.03M | 5.69M | 4.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -15.90K | -22.00K | -45.30K | -77.80K | -400.90K |
| Total Operating Expenses | 22.50M | 21.06M | 23.94M | 22.95M | 20.71M |
| Operating Income | -21.20M | 8.40M | -23.18M | -22.95M | -4.00M |
| Income Before Tax | -17.99M | 6.36M | -25.17M | -20.43M | -5.36M |
| Income Tax Expenses | 3.40K | -- | -- | -- | 1.10K |
| Earnings from Continuing Operations | -17.99M | 6.36M | -25.17M | -20.43M | -5.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.99M | 6.36M | -25.17M | -20.43M | -5.36M |
| EBIT | -21.20M | 8.40M | -23.18M | -22.95M | -4.00M |
| EBITDA | -20.79M | 8.82M | -22.76M | -22.51M | -3.53M |
| EPS Basic | -0.18 | 0.06 | -0.25 | -0.21 | -0.06 |
| Normalized Basic EPS | -0.11 | 0.04 | -0.16 | -0.13 | -0.04 |
| EPS Diluted | -0.18 | 0.06 | -0.25 | -0.21 | -0.06 |
| Normalized Diluted EPS | -0.11 | 0.04 | -0.16 | -0.13 | -0.04 |
| Average Basic Shares Outstanding | 99.99M | 99.84M | 99.55M | 99.39M | 86.74M |
| Average Diluted Shares Outstanding | 99.99M | 100.86M | 99.55M | 99.39M | 86.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
